Bayer AG

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

CureVac B.V

The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.

CVAC Soars on Bayer COVID-19 Vaccine Collaboration

The German biotech struck a deal with chemicals-and-drugs giant Bayer to accelerate the development and supply of its Covid-19 vaccine candidate.

CureVac Forms Covid-19 Vaccine Alliance With Bayer. The Stock Is Surging.

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on Thursday.

CureVac strikes COVID-19 vaccine alliance deal with Bayer

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.

CureVac strikes COVID-19 vaccine alliance deal with Bayer -Bild

LEVERKUSEN, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors included Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital as well as existing investors, including New Enterprise Associates (NEA), 8VC, Amgen Ventures and Lux Cap

Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform

Veracyte

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte's Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients' tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive i

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and the humanitarian organization Direct Relief today announced a new grant program designed to help address financial and educational barriers to contraceptives, enabling women to make powerful decisions about their families and their futures with the help of their healthcare providers. Direct Relief has identified four health clinics that will be awarded $40,000 each to develop programs that expand access to contraceptives for underserved or underinsured

Bayer and Direct Relief Partnership Expands Access to Contraceptives with New Grant Initiative

WHIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Tempus xT broad-panel genomic sequencing assay, for a subset of patients with metastatic

Bayer and Tempus Initiate Collaboration to Advance Patient Access to Genomic Testing and Precision Medicine

INDIANOLA, Pa.--(BUSINESS WIRE)--Bayer Radiology is announcing Radimetrics® v3.0, the newest evolution of its enterprise dose management application. The newly designed system supports many of the latest accreditation standards on dose reporting and tracking, protocol management, and benchmarking, along with offering the latest in cyber security. Radimetrics 3.0 helps patient-care teams report, track, and manage radiation dose and contrast dose throughout the chain of care with increased functi

Bayer Radiology Announces Transformation of Radimetrics®

Bayer (BAYRY) inks a deal with Atara to sell the latter's to -generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors.

Bayer (BAYRY) Inks Deal With Atara for CAR-T Cell Therapies

Aflac

Bristol-Myers

Bank of Nova Scotia

Cisco Systems

Federal Realty Investment Trust

General Dynamics

Intel

Merck

Prudential Financial

Simon Property Group

Unum

The time has come once again to look at what sort of companies you'll want to be buying, this time as we move into December 2020. Rather than offering some sort of collective "list" that could potentially be hard to offer a clear overview, I go sector by sector and present 1-2 alternatives.

December 2020 Stocks: Financials, Real Estate, Industrials, IT, And Pharma

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Fund awarded a $25,000 grant to Township of Hanover as Bayer unveiled new HQ sign dedicated to employees working through COVID pandemic crisis.

Bayer Dedicates New Sign to Employees and Bayer Fund Donates $25,000 to Hanover Emergency Responders

Bayer said it was setting up an organisation within its healthcare division to speed up and support cell and gene therapy development, following recent takeovers.

Bayer sets up cell and gene platform to foster purchased biotech firms

Elanco Animal Health Inc

Elanco Animal Health Inc (NYSE: ELAN) in a filing with the U.S. Securities and Exchange Commission on Monday disclosed that German pharma and life sciences company Bayer AG (OTC: BAYRY) is offloading a substantial stake it holds in Elanco through a public offering and generate $1.6 billion in proceeds. In August this year, Bayer acquired 72.9 million Elanco shares after the sale of Bayer's Animal Health business segment.

Bayer Sells $1.6B Stake In Elanco Animal Health

A federal judge has rejected Bayer AG's proposed $648 million settlement of class-action litigation by cities and other claimants over contamination from polychlorinated biphenyls, or PCBs, made by the former Monsanto Co.

U.S. judge rejects $648 million Bayer PCB contamination settlement

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Lockheed Martin

Altria

Philip Morris

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The December 2020 Heat Map

Bayer waded deeper into digital health with its  G4A Digital Health Partnerships accelerator program , in which it'll collaborate with five new startups from around the world on digital health solutions, including digital therapeutics (DTx) for chronic conditions, personalized medicine, and AI-driven disease management.

Bayer doubles down on digital health—making it an early mover in the slow-to-digitize pharma space

ST. LOUIS--(BUSINESS WIRE)--Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded $3.9 million in grants to 80 charities and non-profit organizations throughout the United States, $300,000 of which is dedicated to supporting initiatives related to COVID-19. Each grant will go toward a program that contributes to one or more of Bayer Fund's key focus areas: health and wellness, food and nutrition, community development and STEM Education. The St. Louis Area Foodbank, Urba

Bayer Fund Awards $3.9 Million in Grants throughout the United States

All growers are not created equal. At least, that was the mindset that Bayer and other agriculture giants had — until now.   While many farmers are capable of growing standard soybean crops, companies like Bayer often release specific seeds that can produce higher yields or healthier end-products. Those crops require more oversight on the part of a provider like Bayer — including site visits to watch the seeds get planted, for example — to ensure farmers are complying with the more stringent growing protocols. That's why Bayer and others have to limit access to those speciality product.

Why it was a 'no brainer' for ag giant Bayer to launch the industry's first blockchain initiative to track crops from seed-to-sale with startup partner BlockApps

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, reduced the risk of cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), with or without history of cardiovascular disease (CVD).1,2 The findings were presented in a Late-Breaking session today at the American Heart Associ

Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 Diabetes

With immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.

Investors Wish They Could Vote These 2 Healthcare CEOs Out

EMERYVILLE, Calif., US, and LEVERKUSEN, Germany--(BUSINESS WIRE)--Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a USD 65 million Series A financing round and emerged from stealth mode today. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. CRISPR-based gene editing is one of the most important discoveries in recent years,

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Alexion Pharma

Amgen

Regeneron Pharmaceuticals

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.

These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable

A court-appointed mediator on Monday said Bayer AG has made "substantial progress" toward resolving tens of thousands of remaining claims that its Roundup weedkiller causes cancer.

Bayer makes 'substantial progress' in Roundup cancer lawsuits, mediator says

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of the investigational drug finerenone, for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Finerenone is a potential first-in-class investigational non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that d

Bayer Submits Regulatory Applications for Investigational Drug Finerenone in the U.S. and the EU for Patients with Chronic Kidney Disease and Type 2 Diabetes

News for Bayer AG Stock (BAYRY)